Physician profile
Aditya Gupta
NPI 1497755615
$2,978.34
in general payments reported to CMS, 2019-2025
27 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $27.17 · 2021: $228 · 2022: $46.58 · 2023: $518 · 2024: $992 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.17 |
| Education | $109.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $795.29 | 2023-2024 | Impella |
| Glaxosmithkline, LLC. | $304.74 | 2019-2025 | Trelegy Ellipta, Nucala |
| Ethicon INC. | $246.91 | 2019 | |
| Grifols USA, LLC | $165.97 | 2024-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $150.75 | 2019-2024 | |
| Caris Mpi, INC. | $140.18 | 2025 | Mi Cancer Seek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.05 | 2020-2024 | |
| Genentech USA, INC. | $123.14 | 2019 | |
| Lilly USA, LLC | $109.52 | 2025 | |
| Genzyme Corporation | $99.43 | 2019-2025 | |
| Electromed, INC. | $83.27 | 2024-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $81.12 | 2023-2024 | Opsumit, Uptravi |
| Csl Behring | $70.54 | 2023-2024 | Kcentra |
| Ekos Corporation | $66.61 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $56.07 | 2021-2025 | Breztri, Airsupra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $45.02 | 2019-2024 | Yupelri |
| Abbott Laboratories | $41.16 | 2023 | Proclaim |
| Pulmonx Corporation | $39.68 | 2019-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Takeda Pharmaceuticals U.S.A., INC. | $34.09 | 2021-2022 | |
| Coloplast Corp | $34.09 | 2021 | |
| Ucb, INC. | $33.50 | 2025 | Bimzelx |
| Insmed, INC. | $29.28 | 2019-2021 | |
| United Therapeutics Corporation | $23.26 | 2023 | Tyvaso |
| Sandoz INC. | $21.23 | 2025 | Treprostinil |
| Merck Sharp & Dohme LLC | $17.37 | 2022 | |
| Viiv Healthcare Company | $17.08 | 2024 | Rukobia |
| Mayne Pharma Commercial LLC | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.